Jump to content

JZL195

From Wikipedia, the free encyclopedia
JZL195
Names
Preferred IUPAC name
4-Nitrophenyl 4-[(3-phenoxyphenyl)methyl]piperazine-1-carboxylate
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • InChI=1S/C24H23N3O5/c28-24(32-22-11-9-20(10-12-22)27(29)30)26-15-13-25(14-16-26)18-19-5-4-8-23(17-19)31-21-6-2-1-3-7-21/h1-12,17H,13-16,18H2
    Key: QNYRAEKLMNDRFY-UHFFFAOYSA-N
  • c1ccc(cc1)Oc2cccc(c2)CN3CCN(CC3)C(=O)Oc4ccc(cc4)[N+](=O)[O-]
Properties
C24H23N3O5
Molar mass 433.464 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

JZL195 is a potent inhibitor of both fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), the primary enzymes responsible for degrading the endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG), respectively.[1]

See also

[edit]

References

[edit]
  1. ^ Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, Burston JJ, Sim-Selley LJ, Lichtman AH, Wiley JL, Cravatt BF (December 2009). "Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo". Proceedings of the National Academy of Sciences of the United States of America. 106 (48): 20270–5. Bibcode:2009PNAS..10620270L. doi:10.1073/pnas.0909411106. PMC 2787168. PMID 19918051.